Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment

BMC Medical Genomics

Volumn 4, Issue , 2011, Pages

  Wang, Ena ^a   Bussom, Scott ^b   Chen, Jinguo ^a   Quinn, Courtney ^a   Bedognetti, Davide ^a,c   Lam, Wing ^b   Guan, Fulan ^b   Jiang, Zaoli ^b   Mark, Yichao ^a   Zhao, Yingdong ^d   Stroncek, David F ^a   White, Jeffrey ^d   Marincola, Francesco M ^a   Cheng, Yung Chi ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHINESE DRUG; IRINOTECAN; PHY 906; UNCLASSIFIED DRUG; CAMPTOTHECIN; DRUG DERIVATIVE; HERBACEOUS AGENT; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHRONIC INFLAMMATION; COLON TUMOR; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; IMMUNE DEFICIENCY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN; SUBCUTANEOUS TISSUE TUMOR; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; TUMOR REJECTION; ANIMAL; CELL PROLIFERATION; CELL STRAIN HEPG2; CHINESE MEDICINE; DRUG INTERACTION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; ORGAN SIZE; PATHOLOGY; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALIA; MUS;

ANIMALS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG INTERACTIONS; DRUGS, CHINESE HERBAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; IMMUNITY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER; MACROPHAGES; MEDICINE, CHINESE TRADITIONAL; MICE; ORGAN SIZE; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPLEEN; TUMOR MICROENVIRONMENT;

EID: 79955755861     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-4-38     Document Type: Article

References (36)

1. Evidence from the Cochrane Collaboration for Traditional Chinese Medicine therapies. E Manheimer S Wieland E Kimbrough K Cheng BM Berman, J Altern Complement Med 2009 15 1001 1014 10.1089/acm.2008.0414 19757977
2. From traditional Chinese medicine to rational cancer therapy. T Efferth PC Li VS Konkimalla B Kaina, Trends Mol Med 2007 13 353 361 10.1016/j.molmed. 2007.07.001 17644431 (Pubitemid 47126989)
3. Bioactivity-guided identification and cell signaling technology to delineate the immunomodulatory effects of Panax ginseng on human promonocytic U937 cells. DC Lee CL Yang SC Chik JC Li JH Rong GC Chan AS Lau, J Transl Med 2009 7 34 10.1186/1479-5876-7-34 19442267
4. The four-herb chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. W Lam S Bussom F Guan Z Jiang W Zhang EA Gullen S-H Liu Y-C Cheng, Science Transl Med 2010 2 45ra59
5. How an 1,800-year-old herbal mix heals the gut. E Callaway, Nature News 2011 http://www.nature.com/news/2010/100818/full/news.2010.417.html
6. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Y Yen S So M Rose MW Saif E Chu SH Liu A Foo Z Jiang T Su YC Cheng, Anticancer Res 2009 29 4083 4092 19846955
7. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. MW Saif F Lansigan S Ruta L Lamb M Mezes K Elligers N Grant ZL Jiang SH Liu YC Cheng, Phytomedicine 2010 17 161 169 10.1016/j.phymed.2009.12.016 20092990
8. A comprehensive platform for quality control of botanical drugs (Phytomics QC) - A case study of Huanggi Tang (HGT) and PHY906. R Tilton A Paiva J Guan R Marathe Z Jiang W van Eindhoven Z Prusoff J Bjoraker H Wang SH Liu YC. Cheng, Chinese Medicine 2010 5 30 10.1186/1749-8546-5-30 20727161
9. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass Spectrometry (LC/MS/MS). W Zhang MW Saif GE Dutschman X Li W Lam S Bussom Z Jiang M Ye E Chu YC Cheng, J Chromatogr A 2010 1217 5785 5793 10.1016/j.chroma.2010.07.045 20696432
10. High fidelity mRNA amplification for gene profiling using cDNA microarrays. E Wang L Miller GA Ohnmacht E Liu FM Marincola, Nature Biotech 2000 17 457 459 (Pubitemid 30217539)
11. Analysis of Gene Expression Data Using BRB-Array Tools. R Simon A Lam MC LI M Ngan S Menenzes Y Zhao, Cancer Inform 2007 3 11 17 19455231 (Pubitemid 47075796)
12. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. S Kummar MS Copur M Rose S Wadler J Stephenson M O'Rourke W Brenckman R Tilton S-H Liu Z Jiang YC Cheng E Chu,, et al. Clin Colorec Cancer 2010
13. Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. VE Kagan HA Bayir NA Belikova O Kapralov YY Tyurina VA Tyurin J Jiang DA Stoyanovsky P Wipf PM Kochanek JS Greenberger B Pitt AA Shvedova G Borisenko, Free Radic Biol Med 2009 46 1439 1453 10.1016/j.freeradbiomed.2009.03.004 19285551
14. Interferon gamma (IFNgamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. K Suk I Chang YH Kim S Kim JY Kim H Kim MS Lee, J Biol Chem 2001 276 13153 13159 10.1074/jbc.M007646200 11278357
15. Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs. JH Lee T Chun SY Park SB Rho, Biochim Biophys Acta 2008 1783 1654 1662 10.1016/j.bbamcr.2008.04.006 18472010
16. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. A Takaoka H Yanai S Kondo G Duncan H Negishi T Mizutani S Kano K Honda Y Ohba TW Mak T Taniguchi, Nature 2005 434 243 249 10.1038/nature03308 15665823 (Pubitemid 40388058)
17. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. BJ Barnes MJ Kellum KE Pinder JA Frisancho PM Pitha, Cancer Res 2003 63 6424 6431 14559832 (Pubitemid 37255192)
18. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. BJ Barnes MJ Kellum AE Field PM Pitha, Mol Cell Biol 2002 22 5721 5740 10.1128/MCB.22.16.5721-5740.2002 12138184 (Pubitemid 34815822)
19. Selection and validation of endogenous reference genes using a high throughput approach. P Jin Y Zhao Y Ngalame MC Panelli D Nagorsen V Monsurro' K Smith N Hu H Su PR Taylor FM Marincola E Wang, BMC Genomics 2004 5 55 10.1186/1471-2164-5-55 15310404
20. Immunological aspects of cancer chemotherapy. L Zitvogel L Apetoh F Ghiringhelli G Kroemer, Nat Rev Immunol 2008 8 59 73 10.1038/nri2216 18097448
21. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. AS Jassar E Suzuki V Kapoor J Sun MB Silverberg L Cheung MD Burdick RM Strieter LM Ching LR Kaiser SM Albelda, Cancer Res 2005 65 11752 11761 10.1158/0008-5472.CAN-05-1658 16357188 (Pubitemid 41821737)
22. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. ZJ Roberts N Goutagny PY Perera H Kato H Kumar T Kawai S Akira R Savan ED van KA Fitzgerald HA Young LM Ching SN Vogel, J Exp Med 2007 204 1559 1569 10.1084/jem.20061845 17562815 (Pubitemid 47049627)
23. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facets of oncolytic therapy. A Worschech N Chen YA Yu Q Zhang Z Pos S Weibel V Raab M Sabatino A Monaco H Liu V Monsurrá RM Buller DF Stroncek E Wang AA Szalay FM Marincola, BMC Genomics 2009 10 301 10.1186/1471-2164-10-301 19583830
24. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. MC Panelli E Wang G Phan M Puhlman L Miller GA Ohnmacht H Klein FM Marincola, Genome Biol 2002 3 ESEARCH0035 12184809
25. Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. MC Panelli M Stashower HB Slade K Smith C Norwood A Abati PA Fetsch A Filie SA Walters C Astry E Aricá Y Zhao S Selleri E Wang FM Marincola, Genome Biol 2006 8 8
26. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. XE Dong N Ito MT Lotze RA Demarco P Popovic SH Shand S Watkins S Winikoff CK Brown DL Bartlett HJ Zeh, J Immunother 2007 30 596 606 10.1097/CJI.0b013e31804efc76 17667523 (Pubitemid 47229694)
27. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. L Apetoh F Ghiringhelli A Tesniere A Criollo C Ortiz R Lidereau C Mariette N Chaput JP Mira S Delaloge F André T Tursz G Kroemer L Zitvogel, Immunol Rev 2007 220 47 59 10.1111/j.1600-065X.2007.00573.x 17979839 (Pubitemid 350045573)
28. IFNalpha sensitizes ME-180 human cervical cancer cells to TNFalpha-induced apoptosis by inhibiting cytoprotective NF-kappaB activation. K Suk YH Kim I Chang JY Kim YH Choi KY Lee MS Lee, FEBS Lett 2001 495 66 70 10.1016/S0014-5793(01)02335-3 11322949 (Pubitemid 32367975)
29. The IRF family transcription factors in immunity and oncogenesis. T Tamura H Yanai D Savitsky T Taniguchi, Annu Rev Immunol 2008 26 535 584 10.1146/annurev.immunol.26.021607.090400 18303999 (Pubitemid 351600385)
30. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. G Hu ME Mancl BJ Barnes, Cancer Res 2005 65 7403 7412 10.1158/0008-5472.CAN-05-0583 16103093 (Pubitemid 41161274)
31. The immunologic constant of rejection. E Wang A Worschech FM Marincola, Trends Immunol 2008 29 256 262 10.1016/j.it.2008.03.002 18457994
32. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. K Honda T Taniguchi, Nat Rev Immunol 2006 6 644 658 10.1038/nri1900 16932750 (Pubitemid 44298214)
33. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. A Schoenemeyer BJ Barnes ME Mancl E Latz N Goutagny PM Pitha KA Fitzgerald DT Golenbock, J Biol Chem 2005 280 17005 17012 10.1074/jbc.M412584200 15695821 (Pubitemid 41389162)
34. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. AK Pandey Y Yang Z Jiang SM Fortune F Coulombe MA Behr KA Fitzgerald CM Sassetti MA Kelliher, PLoS Pathog 2009 5 1000500 10.1371/journal.ppat.1000500 19578435
35. Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation. X Ouyang H Negishi R Takeda Y Fujita T Taniguchi K Honda, Biochem Biophys Res Commun 2007 354 1045 1051 10.1016/j.bbrc.2007.01.090 17275788 (Pubitemid 46216241)
36. IRF5 is required for late-phase TNF secretion by human dendritic cells. T Krausgruber D Saliba G Ryzhakov A Lanfrancotti K Blazek IA Udalova, Blood 2010